Weintraub’s Client, CESCA, Announces Pricing of Public Offering of Common Stock and Warrants
Published: June 13, 2014
RANCHO CORDOVA, Calif., June 13, 2014 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today the pricing of an underwritten public offering of 7,530,000 Units, consisting of an aggregate of 7,530,000 shares of the Company’s common stock and warrants to purchase 2,259,000 shares of the Company’s common stock, at a price of $1.50 per Unit. Each warrant entitles the holder to purchase 0.30 of a share of common stock. The warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance. The shares of common stock and warrants comprising the Units are immediately separable. All of the Units in the offering are being sold by Cesca. The gross proceeds to Cesca from this offering are expected to be approximately $11.3 million, excluding any future proceeds from the potential exercise of the warrants and before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cesca. The offering is expected to close on or about June 18, 2014, subject to the satisfaction of customary closing conditions.
To view the full press release click the link above.